Clinical evaluations, post-market registries, and pivotal trials demonstrate that Barostim therapy achieves high success rates in improving functional capacity, quality of life, and exercise tolerance for heart failure patients who remain symptomatic despite optimal guideline-directed medical therapy. Clinical data highlights significant improvements in patient symptom scores, reductions in heart failure hospitalizations, and enhanced cardiac performance metrics. By engaging the body's natural baroreflex mechanisms to regulate autonomic output, the therapy offers a valuable alternative for patients who do not qualify for cardiac resynchronization therapy.